Verrica Pharmaceuticals Inc. (VRCA)

Verrica Pharmaceuticals Inc (VRCA) is a biopharmaceutical company that develops and commercializes dermatological treatments. The company's lead product candidate is VP-102, a drug-device combination product for the treatment of molluscum contagiosum and common warts. VP-102 is a proprietary drug-device combination of cantharidin 0.7% and a single-use applicator that enables precise topical dosing. The product has completed Phase 3 trials and is currently under review by the U.S. Food and Drug Administration (FDA).

In addition to VP-102, Verrica has a pipeline of other product candidates in preclinical and clinical development, including VP-103 for the treatment of plantar warts and common warts, and VP-104 for the treatment of external genital warts.

Verrica Pharmaceuticals was founded in 2013 and is headquartered in West Chester, Pennsylvania.